Skip to content
Peptide Evidence Registry

Comparison Centre

Two compounds, the same questions, no cherry-picking

Marketing compares compounds on whichever measure flatters them. This compares them on the same fields every time — including the awkward ones like how much human safety data exists. Every score here rates the evidence, not the compound: a higher number means stronger or more mature research, not that something is safer or works better.

Sharing keeps the two compounds you picked.

How to read these scores

Every number here rates the evidence, not the compound. They are editorial 0-100 strength ratings, not percentages, and not a rating out of five stars.

  • Human efficacy evidence strength — Higher = more and better-quality human evidence. It does not mean the effect is bigger or that the compound works for you.
  • Preclinical evidence strength — Higher = more animal, tissue or cell research. Preclinical results are a starting point, not proof of a human benefit.
  • Human safety evidence strength — Higher = more mature, better-documented human safety data. It does not mean the compound is safer than one with a lower number. A score of 80 does not mean “80% safe”.
  • Evidence level (L0-L5) — the strongest type of study behind the compound, from anecdote (L0) to large replicated human trials (L5). It is a description of the study evidence, not a quality, safety or recommendation rating.
  • Confidence — how likely we think it is that this rating changes as new research lands. Low confidence means the picture is unsettled, not that the compound is bad.

None of these ratings is medical advice, a safety guarantee, or a recommendation to use anything. How we grade evidence.

Pemvidutide

An investigational GLP-1/glucagon dual agonist now developed primarily for serious liver disease, not weight loss.

L3Early human studiesIn clinical trials
Full profile

Mazdutide

A GLP-1/glucagon dual agonist developed largely in Chinese trial populations.

L4Good human trialsApproved in some countries only · NMPA (China)
Full profile

How far human research has progressed

Pemvidutide

Phase 2b reported; Phase 3 MASH trial initiated August 2026

Mazdutide

Approved in China (2025); development status elsewhere not established

Claim-specific benefit evidence

A human exposure study or trial registration does not establish that the claimed benefit occurs.

Pemvidutide

Not separately assessed; see the full profile.

Mazdutide

Not separately assessed; see the full profile.

Human research context

Pemvidutide

Phase 2b reported; Phase 3 MASH trial initiated August 2026

Mazdutide

Approved in China (2025); development status elsewhere not established

Human efficacy evidence strength

Higher = more and better-quality human evidence. It does not mean the effect is bigger or that the compound works for you.

Pemvidutide

Strength of the human efficacy evidence40 of 100 evidence strength

Mazdutide

Strength of the human efficacy evidence60 of 100 evidence strength

Preclinical (animal / lab) evidence strength

Higher = more animal, tissue or cell research. Preclinical results are a starting point, not proof of a human benefit.

Pemvidutide

Strength of the animal and lab evidence60 of 100 evidence strength

Mazdutide

Strength of the animal and lab evidence75 of 100 evidence strength

Human safety evidence strength

Higher = more mature, better-documented human safety data. It does not mean the compound is safer than one with a lower number.

Pemvidutide

Strength of the human safety evidence25 of 100 evidence strength

Mazdutide

Strength of the human safety evidence42 of 100 evidence strength

Regulatory status (legal position, not proof it works)

Pemvidutide

Check jurisdiction-specific details in the profile.

Not approved anywhere. A global Phase 3 trial (PERFORMA) in MASH was initiated in August 2026, and the compound holds FDA Breakthrough Therapy designation for MASH based on Phase 2b data. Breakthrough designation speeds up review; it is not approval and not evidence of benefit.

Mazdutide

Named regulators: NMPA (China)

Approved in China by the NMPA: for chronic weight management in June 2025, and for glycaemic control in adults with type 2 diabetes in September 2025. Not approved in the US, UK or EU — a regional approval, not a global one.

Common claims

Pemvidutide

  • · Liver fat and fibrosis improvement in MASH
  • · Weight loss with preserved lean mass

Mazdutide

  • · Meaningful weight loss
  • · Liver fat reduction

How settled our evidence rating is

Pemvidutide

Low confidence in ratingL3Early human studies

Mazdutide

Moderate confidence in ratingL4Good human trials

Cancer-related questions raised by the biology

These are theoretical or monitored questions raised by how a compound works. They are not evidence that it causes cancer.

Pemvidutide

No established human cancer signal for this compound.

Mazdutide

No established human cancer signal; class-level surveillance applies.

What this adds up to, in plain English

Pemvidutide

Preliminary human observations exist, but they may not establish a treatment-attributable benefit.

Mazdutide

Real controlled human trials exist, but questions about approval, how long benefits last, or long-term safety are still open.

A comparison is not a recommendation

Neither column here is an endorsement, and the compound with the higher numbers is not the “better” or “safer” one — it is simply the one with more or better-quality research behind it. Two compounds can both be poorly evidenced, and better-evidenced says nothing about whether either is a sensible idea for a specific person. That is a conversation for a qualified clinician.